This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levett, P. N. Articles by Drebot, M. A. Search for Related Content PubMed PubMed Citation Articles by Levett, P. N. Articles by Drebot, M. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, December 2005, p. 5873-5875, Vol. 43, No. 12
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.12.5873-5875.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Use of Immunoglobulin G Avidity Assays for Differentiation of Primary from Previous Infections with West Nile Virus

P. N. Levett,^1* K. Sonnenberg,² F. Sidaway,¹ S. Shead,³ M. Niedrig,⁴ K. Steinhagen,² G. B. Horsman,¹ and M. A. Drebot³

Provincial Laboratory, Saskatchewan Health, Regina, Saskatchewan, Canada,¹ EUROIMMUN AG, Luebeck, Germany,² National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada,³ Robert Koch Institute, Berlin, Germany⁴

Received 5 July 2005/ Returned for modification 7 September 2005/ Accepted 16 September 2005

Since its introduction in 1999, West Nile virus (WNV) infections have spread rapidly across the North American continent. Diagnosis of acute WNV infection by detection of WNV-specific immunoglobulin M (IgM) is complicated by the persistence of detectable IgM for more than 1 year in some patients. IgG antibody avidity testing was assessed as a supplemental assay in the diagnosis of current infections. Three groups of serum samples were assayed in parallel by two different IgG avidity test systems (indirect immunofluorescence test [IIFT] and prototype enzyme-linked immunosorbent assay [ELISA]; EUROIMMUN, Luebeck, Germany). Group I (40 sera taken between 2 and 9 days after the onset of influenza-like symptoms) and group II (40 sera taken between 10 and 43 days after onset) were acute and convalescent specimens from patients with a positive anti-WNV IgM test (ELISA; Focus Diagnostics, Cypress, CA). Group III consisted of 43 patient sera collected between 6 and 12 months after infection. IgG antibodies specific for WNV were detected in 38% (ELISA) and 50% (IIFT) of group I sera, in 90% (ELISA and IIFT) of group II sera, and in 100% (ELISA and IIFT) of group III sera. Low-avidity IgG antibodies were demonstrated in 86% (ELISA) and 95% (IIFT) of IgG-positive patient samples taken between 2 and 43 days after the onset of symptoms (groups I and II). High-avidity IgG antibodies were detected in 100% of group III sera obtained 6 months or more after the onset of symptoms (ELISA and IIFT). IgG avidity tests for WNV infections are rapid and simple to perform. The determination of IgG avidity provides additional diagnostic certainty in differentiating between recently acquired and previous infections with WNV.

---

* Corresponding author. Mailing address: 3211 Albert Street, Regina, Saskatchewan S4S 5W6, Canada. Phone: (306) 787-3135. Fax: (306) 787-1525. E-mail: plevett{at}health.gov.sk.ca.

---

Journal of Clinical Microbiology, December 2005, p. 5873-5875, Vol. 43, No. 12
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.12.5873-5875.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Chan, K. H., Sonnenberg, K., Niedrig, M., Lam, S. Y., Pang, C. M., Chan, K. M., Ma, S. K., Seto, W. H., Peiris, J. S. M. (2007). Use of Antibody Avidity Assays for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus Infection. CVI 14: 1433-1436 [Abstract] [Full Text]